and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...

Those include tradipitant, which is under FDA review for delayed gastric emptying (gastroparesis) and in phase 3 for motion sickness, as well as Fanapt follow-up milsaperdone, which is due to be ...

After hours: February 7 at 7:23:36 PM EST ...

After hours: February 7 at 7:23:36 p.m. EST ...